Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

BioNTech SE (BNTX)

NASDAQ
Currency in USD
Disclaimer
92.25
-0.72(-0.77%)
Closed
After Hours
92.30+0.05(+0.05%)

BNTX Comments

another good news and it means bankruptcy for Biontech....heavy manipulation....
what's the good news ?
Can you pls name 1 other vaccine which doesn’t stop you from catching infection, doesn’t stop getting symptomatic even after 3rd dose, doesn’t stop you spreading infection but stops you dying from a disease with avg mortality age >80 & 75% deaths in people with 4 co morbidities
my average is somewhere at 250 and have brought it down to that value after buying in some more. I could wait 2-4 months! any suggestions ?
up to you, but I never average down, it does not make sense..only add when it goes up, when it does down leave the ship when you reached your limit - percentage or absolute - I normally only work with absolute amount....(I have 2 expextions, but these are different animals....)
no am at my limit now. but 250 is the average price of my shares. not sure what to do ? wait for 2-4 months to avoid the losses when it comes up again or leave the ship right now. bcos am sceptical if it keeps dropping and never come back again. for the first time I am clueless with a stock.
falls apart
so what's going on ? this is shattering the bottoms now ? is it concerning now although broadly all the stocks are going towards the south ?
a piece of @♧☆♤X
Reuters-Jan 13; Rapid development and manufacturing changes are made possible by the new mRNA vaccine technology deployed by by Pfizer BioNTech.The new vaccine for Omicron is coming in March, developed by Pfizer Biontech. At first stage, Pfizer BioNTech will manufacture 100 million doses of a new omicron-specific version of its coronavirus vaccine. 🚀🚀🚀
Is that you, Rob?
🚀 Germany's vaccine committee recommended on Thursday that all children between the ages of 12 and 17 receive a COVID-19 booster shot as the country reported a new daily record of more than 81,000 coronavirus infections. The third dose should be an mRNA shot from BioNTech/Pfizer and should be given, at the earliest, three months after the child had their second shot, STIKO said in a statement. The EMA said this week it was reviewing whether to extend the booster approval for Pfizer (NYSE:PFE) shots to adolescents aged 16 and 17, and expected drugmakers to apply for the 12-15 age group as well.🚀
Looks like going deeper :/
: (
ntv: "Studies started on cancer drugs that had not previously been tested in humans and two studies moved into phase two of development. In addition, Biontech has an influenza vaccine in the first phase of clinical development and plans to begin human clinical trials this year with four vaccine candidates for herpes zoster, malaria, tuberculosis and herpes simplex.". I am not worried investing in this stock.
This would be very necessary to habe other revenue streams. To develop and have a blockbuster drug is not easy...also, the vaccine market is not really an easy market (that is the reason the major drug companies pulled out and have just partners and offer their manufacturing and production).
Look at the presentation from the conference: Further COVID-19 vaccine launches of new formulation, pediatric dosage form, andvariant adapted vaccine. Also, expand organization in Europe, the U.S., Asia, and Africa and deploy pandemic response capability.
revenue guidance from BNTX at annual health care conference flat or lower for 2022 than 2021 (2021 = 16 to 17b; 2022 = 13b to 17b). Big difference in lower end, around 20%.
🚀🔆 BioNTech and InstaDeep Ltd  today announced the development of a new computational method that analyses worldwide available sequencing data and predicts high-risk variants of SARS-CoV-2. The Early Warning System (EWS) developed in collaboration by BioNTech and InstaDeep is based on artificial intelligence (AI) calculated immune escape and fitness metrics. Early flagging of potential high-risk variants could be an effective tool to alert researchers, vaccine developers, health authorities and policy makers, thereby providing more time to respond to new variants of concern🚀🔆
I really don’t understand. 2 nd doses, boosters, biontech’ s investments for other diseases.. Should be much more above of current value. My estimation failed 🤦‍♂️🤦‍♂️🤦‍♂️
Trend reversal. Now BNTX is coming back to its old shape. New and frequently reported mutatons will literally boost the business. Just listen to the words of Pfizer CEO Bourla.
🚀🚀🚀🚀🔥🔥🔥
🚀🔆BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies. Collaboration leverages BioNTech’s proprietary multimodal immunotherapy expertise with Crescendo’s proprietary Humabody® VH platform to develop precision immunotherapies, including mRNA-based antibodies and engineered cell therapies against targets selected by BioNTech. 🚀🚀🚀🚀🚀🚀🚀
is it going to go further down this week ?
Yep!
nvax which is not yet selling vaccines is green and moderna which has much lesser profits than bntx is green. but bntx is -3 percent. great
it doesn’t make sense to comment on daily fluctuations. As you can see you can be contradicted in 30 mins
Adding...Vaccination is our best defense against COVID-19, including the circulating variants, and shortening the length of time between completion of primary series and a booster dose may help reduce waning immunity," Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, said.
🚀The FDA earlier this week cut the interval to get a booster dose of Pfizer and BioNTech COVID-19 vaccine, based on mRNA technology like Moderna's, to five months from six.
FED and inflation pushing indexes down. That’s the only reason BNTX is cheap (?) now. But daily selling trend (heikin hashi) hasn’t slowed down yet as far as I see.
BBC UK- Jan 7-2022; Dr Ravindra Gupta, professor of Clinical Microbiology from University of Cambridge; In an interview where he talks & explains why COVID-19 caused by omicron variant is less virulent than earlier variants, Ravindra Gupta has gone on to say that omicron looks like “an evolutionary mistake” & the next variant will be MORE SEVERE.
Good entry point for building up a new position ( not for current holders). recommend to have an exit strategy (stop loss). when it goes up, pyramid up, if down get out according to your exit strategy.
CDC now urges everyone 12 and older to get BNTX COVID boosterLast Updated: Jan. 5, 2022 at 9:00 p.m
Albert Bourla, Pfizer CEO, has just confirmed, that he expects annual vaccinations against COVID-19 in the long-time future. An Omicron specific vaccine will be available in March. There are available capacities to produce billions of doses of this adapted vaccine version even in 2022.
(Reason: Vaccination and infection immunity won't last longer than a few months. There is no way to change that situation to the virus' strength and its capability to mutate frequently.)
steeper uptrend broke https://invst.ly/x1mw3
does it mean going down further ?
...
...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.